Minerva Neurosciences SG&A Expenses 2013-2024 | NERV

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Minerva Neurosciences sg&a expenses from 2013 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Minerva Neurosciences sg&a expenses from 2013 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$76.9B
Takeda Pharmaceutical (TAK)	$43.9B
Merck (MKKGY)	$20.8B
Astellas Pharma (ALPMY)	$20.2B
Sandoz Group AG (SDZNY)	$19.6B
United Therapeutics (UTHR)	$17.7B
Summit Therapeutics (SMMT)	$15.4B
Neurocrine Biosciences (NBIX)	$12.7B
Shionogi (SGIOY)	$12.3B
Catalent (CTLT)	$10.9B
Madrigal Pharmaceuticals (MDGL)	$7.4B
Jazz Pharmaceuticals (JAZZ)	$6.9B
Orion OYJ (ORINY)	$6.8B
Ionis Pharmaceuticals (IONS)	$5.7B
Corcept Therapeutics (CORT)	$5.7B
Crinetics Pharmaceuticals (CRNX)	$4.7B
PTC Therapeutics (PTCT)	$3.3B
Dyne Therapeutics (DYN)	$3B
Catalyst Pharmaceuticals (CPRX)	$2.7B
Arrowhead Pharmaceuticals (ARWR)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Soleno Therapeutics (SLNO)	$2.2B
NewAmsterdam Pharma (NAMS)	$2B
Recursion Pharmaceuticals (RXRX)	$2B
Centessa Pharmaceuticals (CNTA)	$1.8B
Harrow (HROW)	$1.7B
Ocular Therapeutix (OCUL)	$1.7B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Xencor (XNCR)	$1.6B
Ardelyx (ARDX)	$1.5B